|Title||Health / Medicine / Pharmaceutical Negotiation Role-Play: Teflex Products|
|Year of Publication||1991|
|Authors||Susskind, L, Lawrence, J|
|Keywords||angry public, BATNA, bluffing, brainstorming, competition, consensus, consensus building, cooperation, cooperative, dealing with an angry public, dispute, interests, mutual gain, mutual gains, mutually beneficial, negotiation, PON, teflex, Teflex Products|
Five-party, multi-issue negotiation among representatives of a pharmaceutical company, a medical drug manufacturer, and three consumer organizations over the delayed release of a new drug
|Full Text|| |
Midland Pharmaceutical Company has developed Renaid, a breakthrough drug that moderates kidney damage due to high blood pressure. In order to make Renaid profitable, a product called Teflex (recently patented by Teflex Products) must be added to allow for a timed-release in the body. Teflex Products and Midland have made a deal giving Midland rights to purchase Teflex, but Teflex Products is ten months late in delivering the first order of Teflex to Midland. This has angered and inconvenienced Midland since Midland has already announced Renaid’s availability to the public. The public is outraged at the delay of the drug due to an apparent monetary dispute between two pharmaceutical companies.
Only Teflex Products knows of the real reason for the delay. In response to Midland’s first order last year, Teflex Products produced a $2.5 million batch of Teflex. Before Teflex Products could deliver the batch to Midland, it received a letter from a disgruntled former mixing room employee, alleging that the Teflex batch had been improperly mixed. Teflex Products has been unable to verify the former employee’s allegations. If the allegations are true, then some Renaid consumers could die, and Teflex Products would be sued and likely go out of business. However, if Teflex Products reveals the possibility of improper mixing to Midland, then Midland might refuse the entire batch of Teflex — causing terrible cash flow, investment, and public relations problems, and possibly causing Teflex Products to go out of business anyway.
The National Science Institute has called a meeting to discuss the Renaid situation. Attending will be the President of Midland Pharmaceutical and his attorney, the chief scientist at Teflex, a representative of the Hypertension Association of America, a representative of Consumer Rights Now! and a representative from the National Consumer Health Council.